Biomarkers of VaccineAdjuvant Potency & Safety

6-8 April 2016, Crowne Plaza Porto, Porto, Portugal

  • Increase font size
  • Default font size
  • Decrease font size


Join the conversation on Twitter – #BVAPS2016

Vaccines have saved millions of lives in both the developing and developed world, and as such the development of safe, efficacious and affordable vaccines to counter poverty related and emerging infectious diseases, cancers and other non-communicable diseases for which no vaccines are currently available has become a top priority for the public, regulators and pharmaceutical companies alike. This new international conference will offer a forum for an update on recent developments and future challenges relating to ‘Biomarkers of Vaccine/Adjuvant Potency and Safety’ – BVAPS 2016.

The inaugural BVAPS 2016 meeting will draw on the latest life science research findings to profile how individuals respond to the different components of vaccines at the cellular, genetic and molecular level. Identification and characterization of new biomarkers useful to predict immunogenicity, efficacy and reactogenicity of vaccines given systemically or mucosally will be a main focus of the conference along with discussions on new ways to identify and classify these biomarkers. The impact of genetic background and age on the vaccine efficacy and safety will also be covered by the meeting. It is envisaged that identification of novel ways to better understand the mechanisms of actions of vaccines and adjuvants at all stages of development will enable the acceleration of the development and introduction of a new generation of safer and more effective vaccines. Recent development in cutting-edge technologies such as omics and systems vaccinology alongside state-of-the-art immunological methods that enable in-depth analysis of vaccine immunogenicity, efficacy and safety will also be a focus of the BVAPS 2016 meeting.

Advisory Scientific Panel

Co-Chairs: Ali Harandi (University of Gothenburg, Gothenburg, Sweden) and Nathalie Garcon (BIOASTER, Lyon, France)

Steven Reed (IDRI, Seattle, Washington, USA)
Bali Pulendran (Emory University, Atlanta, Georgia, USA)
Peter Andersen (Statens Serum Institut, Copenhagen, Denmark)
Arnaud Didierlaurent (GlaxoSmithKline Vaccines, Rixensart, Belgium)
Ken J. Ishii (NIBIOHN, University of Osaka, Osaka, Japan)
Donata Medaglini (University of Siena, Siena, Italy)
Ingeleif Jonsdottir (University of Iceland, Reykjavik, Iceland)
Quentin Sattentau (University of Oxford, Oxford, UK)
Behazine Combadiere (Universite Pierre and Marie Curie/INSERM, Paris France)
Tom H.M. Ottenhoff (LUMC, University of Leiden, Leiden, The Netherlands)
Ole Olesen (European & Developing Countries Clinical Trial Partnership, The Hague, The Netherlands)
Daniel Zak (The Center for Infectious Disease Research, Seattle, Washington, USA)
Stefan H.E. Kaufmann (MPIIB, Berlin, Germany)

Conference Scope & Main Topics

The main topics covered by the BVAPS 2016 meeting are:

  • Immunological correlates of protection in vaccine research
  • Technological advancement in evaluation of the vaccine-induced immunity
  • Systems vaccinology
  • Omics analysis of diseases and vaccines
  • Molecular signatures of vaccine immunogenicity and safety
  • Biomarkers of vaccine efficacy
  • Biomarkers of mucosal and skin immunity
  • Human genetics and vaccines
  • Vaccines and adjuvants mechanisms of action
  • DAMP/PAMP and particle  adjuvants mechanism
  • Recent and future directions in vaccine research

The BVAPS 2016 meeting will comprise keynote presentations, special sessions, and in addition the BVAPS 2016 Scientific Advisory Panel are calling for oral and poster abstract submissions to be considered for inclusion in the BVAPS 2016 meeting schedule.


BVAPS 2016 Delegates

Login details will be supplied after you have registered for the event.

BVAPS 2016 Sponsors

  • Sclavo
  • Aditec
  • BioAster
  • Aldevron
  • Inovio Pharmaceuticals
  • EVI
  • IDRI

BVAPS 2016 Downloads

BVAPS 2016 Leaflet

BVAPS 2016 Mailing List

E-mail Address
What is 3+2-1?